Wartość Data wypłaty dywidendy organizacji Starpharma Holdings Limited to N/A
Datą ex-dywidendy (Ex-dividend date) to data określająca, czy dywidendy zostaną wypłacone sprzedającemu lub kupującemu. Dywidendy wypłacone za akcje nabyte po dacie dywidendy należą do nowego właściciela.
The ex-dividend date or reinvestment date is an investment term involving the timing of payment of dividends on stocks of corporations, income trusts, and other financial holdings. If a sale is before this date, the dividend belongs to the new owner; if on or after the date, the seller is entitled to the dividend. If a stock is purchased on its ex-dividend date or after, the buyer will not receive the next dividend payment. Instead, the seller gets the dividend. If a stock is purchased before the ex-dividend date, the buyer gets the dividend.
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.